Saluda Medical Inc (ASX: SLD) Share Price and News

Ms Livingstone AC has served as a Director of Saluda Medical Pty Limited and subsequently the Company since January 2013. From December 2016 to November 2025, she served as Chancellor of the University of Technology Sydney. She is also the non-executive chair of Pacific National, and a non executive director of the Australian Ballet and Quasar Satellite Technologies. She also served as a non executive director of the Australian Design Council. From March 2016 to August 2022, she served as a director of the Commonwealth Bank of Australia (ASX:CBA) and as chair of the board from January 2017 to August 2022. From June 1994 to October 2000, she served as CEO of Cochlear Limited (ASX:COH), an implantable hearing medical device company.

Dr Brooke has served as a Director of Saluda Medical Pty Limited and subsequently the Company since October 2020. Since 2020, he has served as Senior Partner of BioScience Managers Pty Limited, an international healthcare investment firm. He has over 30 years of healthcare venture capital management and investment experience. He has also served as director of Cynata Therapeutics Ltd (ASX:CYP) since May 2019, where he currently serves as the non executive chair of the board, Actinogen Medical Ltd (ASX:ACW) since March 2017, where he currently serves as non executive chair of the board, and Acrux Ltd (ASX:ACR) since June 2016.

Mr Godshall has served as a Director of Saluda Medical Pty Limited and subsequently the Company since June 2021 and has served as Chair since February 2022. He is a executive with extensive experience founding, funding, operating, and selling medical device companies. Since July 2024, He has served as chair of the board of directors of Galvanize Therapeutics, Inc, a biomedical platform company. In addition to his role with the Company, he was President, CEO and a director of Shockwave Medical Inc. (Shockwave) a commercial-stage cardiovascular medical device company, from May 2017 until its sale to Johnson & Johnson in May 2024. Prior to Shockwave, from September 2006 to August 2016, he served as CEO of HeartWare International, Inc., which was acquired by Medtronic plc. He also previously served as a director of Eyepoint Pharmaceuticals, Inc.

Mr Faulkner has served as a Director of Saluda Medical Pty Limited and subsequently the Company since June 2019. Since February 2008, he has served as Managing Director of Redmile Group, LLC, a healthcare-focused investment firm. He has also previously served as a director of Augmedix, Inc. and served as chair of the board of Science 37 Holdings, Inc. from October 2021 until March 2024, and as chair of the board of MedAvail Holdings, Inc. from November 2020 until February 2024.

Mr Palmisano has served as a Director of Saluda Medical Pty Limited and subsequently the Company since April 2022. Since August 2021, he has served as a director of RxSight, Inc., a commercial stage medical technology company. He also served as chair of the board of directors and CEO of Priveterra Acquisition Corp. from December 2020 until its business combination with AEON Biopharma, Inc. (AEON) in July 2023. He remains a non executive director of AEON. From September 2011 to November 2020, he served as President and CEO of Wright Medical, a global medical device company, which was acquired by Stryker Corporation. Prior to Wright Medical, from 2008 to 2010, he served as CEO of ev3 Inc., a global endovascular device company, which was acquired by Covidien plc. Prior to ev3, from 2003 to 2007, he served as President and CEO of IntraLase Corp., an ophthalmic laser technology company, which was acquired by Advanced Medical Optics, Inc. He previously served as chair of the board of Avedro, Inc. from June 2014 to June 2019.

Mr Blackford has served as the President and CEO of iRhythm Technologies, Inc., a Nasdaq listed digital healthcare solutions company focused on the advancement of cardiac care, since October 2021. From September 2017 to September 2021, he held various roles, the most recent one as the COO at Dexcom. From February 2009 to September 2017, Mr Blackford held various roles, the most recent one as the CFO at Nuvasive Inc., a medical device company for minimally invasive spine surgery. From June 1999 to September 2009, Mr Blackford was the director of finance and controller of the dental division at Zimmer Holdings, Inc., a medical device company. He has served as an independent member of the board of directors of Alphatec Holdings, Inc. since October 2017 and Paragon 28, Inc. since August 2022.

Mr Mathias has spent more than 30 years of healthcare and medical technology experience, including senior commercial and operational leadership roles at Medtronic, LimFlow and Endologix.

-

-

-

-

-

-